Magle Chemoswed

Bolag

Magle Chemoswed

Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Senaste publicering

I databasen

48 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
MAGLE

Magle Group announces additional drawdown under bridge loan facility

Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") announces that its wholly owned subsidiary Magle Chemoswed AB (the "Borrower") has requested an additional drawdown of SEK 15 million under the bridge loan facility agreement (the "Bridge Loan Agreement") previously entered into with certain existing bondholders, as announced on 27 May 2026, and that the lenders under the Bridge Loan Agreement have, today on 21 August 2026, approved such additional drawdown. The proceeds of the additional drawdown will be applied towards the repayment of SEK 15 million due by 31 August 2026 under the structured repayment schedule agreed with Danske Bank A/S in respect of the Company's credit facility with Danske Bank A/S (the "Danske Bank Facility"), as announced on 30 June 2026.

MAGLE

Disciplinary Committee of Nasdaq Stockholm fines Magle Chemoswed Holding AB (publ) for breach of rulebook

Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") has received a decision from the Disciplinary Committee of Nasdaq Stockholm by which the Company is ordered to pay a fine corresponding to two (2) annual fees, amounting to approximately SEK 550 thousand, for breach of the Nasdaq First North Growth Market Rulebook and the EU Market Abuse Regulation ("MAR") concerning the Company's disclosure of an order received by its subsidiary Magle Biopolymers.

MAGLE

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028 and its senior secured bonds 2026/2028

On 13 July 2026, Magle Chemoswed Holding AB (publ) (the “Company”) announced that it had initiated a written procedure in relation to its (i) senior secured bonds 2025/2028 with ISIN SE0025197403 (the “Initial Bonds”) and (ii) senior secured bonds 2026/2028 with ISIN SE0029503697 (the “Bonus Bonds” and together with the Initial Bonds, the “Existing Bonds”) (the “Written Procedure”), to request the holders of the Existing Bonds to vote in favour of certain waivers and requests in order to implement the New Structure (as defined in the notice of the Written Procedure) by way of consenting to the proposals set out in the notice of the Written Procedure. The full details of the proposals are set out in the notice of the Written Procedure.

MAGLE

The board of Magle Chemoswed Holding AB (publ) proposes that the EGM resolves on voluntary delisting of the company’s shares from Nasdaq First North Growth Market

The board of directors of Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), has today resolved to propose that an extraordinary general meeting resolves on the delisting of the Company's shares from Nasdaq First North Growth Market ("Nasdaq First North"). The resolution is conditional upon the approval of an extraordinary general meeting. Notice of the extraordinary general meeting will be published through a separate press release.

MAGLE

Magle Chemoswed Holding AB (publ) initiates a written procedure to amend the terms and conditions of its senior secured bonds

On 10 July 2026 Magle Chemoswed Holding AB (publ) (the “Company”) announced that it had, inter alia, reached an agreement with certain bondholders representing approximately 78.71 per cent. of the adjusted nominal amount of the Existing Bonds (as defined below) (the “Bondholder Committee”) on an amended debt and equity capital structure for the group.

MAGLE

MAGLE GROUP HAS RESOLVED ON A RESTRUCTURING OF ITS OUTSTANDING DEBT AND CAPITAL STRUCTURE, INCLUDING DEBT-FOR-EQUITY SWAP, ISSUANCE OF SUPER SENIOR BONDS AND DIRECTED SHARE ISSUES

As previously announced, Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") has for some time been in constructive negotiations with bondholders representing approximately 79 per cent of the adjusted nominal amount of the Company's outstanding senior secured bond loan (ISIN SE0025197403) (the “Initial Bonds”) and (ISIN SE0029503697) (the ”Bonus Bonds”, jointly the “Bonds”) (the "Bondholders") regarding a long-term solution for the Company's financing and capital structure. Today, on 10 July 2026, the Company announces that it has reached an agreement with the Bondholders on the key terms for a restructuring of the Company's outstanding bonds and capital structure (the "Restructuring"). As part of the Restructuring, the Board of Directors has today, on 10 July 2026, resolved on (i) a directed share issue of a maximum of 31,980,350 shares (the "Set-Off Issue") at a subscription price of SEK 1.00 per share, corresponding to approximately SEK 31.98 million, to PRS1 ApS ("PRS1") and MB Holding Køge ApS ("MB Holding") (together the "Lenders") conditional upon the subsequent approval by the extraordinary general meeting intended to be held on 26 August 2026 (the “EGM”), and (ii) a directed share issue of a maximum of 7,500,000 shares (the "Directed Issue I"), at a subscription price of SEK 1.00 per share, corresponding to SEK 7.5 million, to PRS1, conditional upon the subsequent approval by the EGM. In addition, the shareholder PRS1 has proposed that the EGM resolves on a directed share issue of a maximum of 11,350,000 shares (the "Directed Issue II", and, together with the Set-Off Issue and the Directed Issue I, the "Investor Share Issues") at a subscription price of SEK 1.00 per share, corresponding to SEK 11.35 million, to the chairman of the board Stig Løkke Pedersen, board member Søren Skjold Mogensen and previous board members Mats Pettersson and Sven-Christer Nilsson, each privately and/or through a company. Through the Investor Share Issues, the Company will receive a total of SEK 50.83 million, of which approximately SEK 31.98 million will be received through set-off against the loans from the Lenders. Furthermore, the Board of Directors intends to resolve, pursuant to the issue authorisation proposed to be granted by the EGM, on directed set-off issues of new shares to the holders of the Bonds in connection with the Restructuring, comprising shares issued as compensation for the debt-for-equity swap, the consent fee, the upfront fee and the underwriting fee, as further described below. A notice convening the EGM and a notice initiating the Written Procedure will be published through a separate press release.